



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2024

Zona glomerulosa derived Klotho modulates aldosterone synthase expression in young female mice

Daryadel, Arezoo ; Tang, Cong ; Xie, Ye ; Peitzsch, Mirko ; Fisi, Viktoria ; Hantel, Constanze ; Loffing-Cueni, Dominique ; Breault, David T ; Penton, David ; Loffing, Johannes ; Beuschlein, Felix

DOI: <https://doi.org/10.1210/endocr/bqae040>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-259087>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

Daryadel, Arezoo; Tang, Cong; Xie, Ye; Peitzsch, Mirko; Fisi, Viktoria; Hantel, Constanze; Loffing-Cueni, Dominique; Breault, David T; Penton, David; Loffing, Johannes; Beuschlein, Felix (2024). Zona glomerulosa derived Klotho modulates aldosterone synthase expression in young female mice. *Endocrinology*, 165(5):bqae040.

DOI: <https://doi.org/10.1210/endocr/bqae040>

Zona Glomerulosa–Derived Klotho Modulates Aldosterone Synthase Expression in Young Female Mice

Arezoo Daryadel,^{1,*} Cong Tang,^{1,*} Ye Xie,¹ Mirko Peitzsch,² Viktoria Fisi,¹ Constanze Hantel,¹ Dominique Loffing-Cueni,³ David T. Breault,^{4,5} David Penton,⁶ Johannes Loffing,³ and Felix Beuschlein^{1,7,8}

¹Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital of Zürich (USZ) and University of Zürich (UZH), 8091 Zurich, Switzerland

²Institute of Clinical Chemistry and Laboratory Medicine, University Hospital and Medical Faculty Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany

³Institute of Anatomy, University of Zürich, 8057 Zurich, Switzerland

⁴Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA

⁵Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA

⁶Electrophysiology Facility, University of Zurich, 8057 Zürich, Switzerland

⁷Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Ludwig-Maximilians-Universität, 81377 Munich, Germany

⁸The LOOP Zurich Medical Research Center, 8044 Zurich, Switzerland

Correspondence: Felix Beuschlein, MD, Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital of Zürich (USZ) and University of Zürich (UZH), Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Raemistrasse 100, CH-8091 Zurich, Switzerland. Email: felix.beuschlein@usz.ch.

*These authors contributed equally to this work.

Abstract

Klotho plays a critical role in the regulation of ion and fluid homeostasis. A previous study reported that haplo-insufficiency of Klotho in mice results in increased aldosterone synthase (*CYP11B2*) expression, elevated plasma aldosterone, and high blood pressure. This phenotype was presumed to be the result of diminished Klotho expression in zona glomerulosa (zG) cells of the adrenal cortex; however, systemic effects on adrenal aldosterone production could not be ruled out. To examine whether Klotho expressed in the zG is indeed a critical regulator of aldosterone synthesis, we generated a tamoxifen-inducible, zG-specific mouse model of Klotho deficiency by crossing *Klotho-flox* mice with *Cyp11b2-CreERT* mice (zG-KI-KO). Tamoxifen-treated *Cyp11b2-CreERT* animals (zG-Cre) served as controls. *Rosa26-mTmG* reporter mice were used for Cre-dependent lineage-marking. Two weeks after tamoxifen induction, the specificity of the zG-Cre line was verified using immunofluorescence analysis to show that GFP expression was restricted to the zG. RNA in situ hybridization revealed a 65% downregulation of Klotho messenger RNA expression in the zG of zG-KI-KO female mice at age 12 weeks compared to control mice. Despite this significant decrease, zG-KI-KO mice exhibited no difference in plasma aldosterone levels. However, adrenal *CYP11B2* expression and the *CYP11B2* promoter regulatory transcription factors, NGFIB and Nurr1, were enhanced. Together with in vitro experiments, these results suggest that zG-derived Klotho modulates *Cyp11b2* but does not evoke a systemic phenotype in young adult mice on a normal diet. Further studies are required to investigate the role of adrenal Klotho on aldosterone synthesis in aged animals.

Key Words: Klotho, aldosterone, zona glomerulosa, CYP11B2, Cre-lox system

Abbreviations: ACTH, adrenocorticotropic; Ang II, angiotensin II; ERK, extracellularly regulated kinase; FGF, fibroblast growth factor; gRNA, guide RNA; KO, knockout; mRNA, messenger RNA; PBS, phosphate-buffered saline; RAAS, renin-angiotensin-aldosterone system; TMX, tamoxifen; zG, zona glomerulosa.

Klotho has been identified as a gene associated with accelerating aging when disrupted and extending lifespan when overexpressed (1–4). Klotho is highly expressed in the kidney and has been implicated as a regulator of fluid and electrolyte balance that might also modulate aldosterone secretion from the zona glomerulosa (zG) of the adrenal cortex. On a molecular level, Klotho functions as a coreceptor of (fibroblast growth factor) FGF receptors to specifically activate the FGF23 signaling pathway (5, 6). Of interest, FGF23 may also be involved in the activation of the local renin-angiotensin-aldosterone system (RAAS), including hyperaldosteronism in cardiac fibrosis and hypertrophy progression (7, 8), chronic kidney disease

(9, 10), diabetic nephropathy (11), and hepatic failure (12). Conversely, aldosterone has been recognized as a powerful stimulator of FGF23 formation in vitro and in vivo by enhancement of store-operated Ca^{2+} entry (13). Furthermore, the interplay of Klotho and the RAAS has been further demonstrated on the basis of downregulation of Klotho by angiotensin II (Ang II) and upregulation of cytochrome P450 (*CYP*) 11B2, which is responsible for aldosterone synthesis in the absence of Klotho (5, 6). Conversely, Klotho downregulates RAAS activity, thus attenuating tissue injury and fibrosis and improving hypertension in experimental chronic kidney disease (6). As adrenal zG cells are the primary source of

circulating aldosterone and CYP11B2 is the specific and rate-limiting enzyme for aldosterone synthesis in zG cells, we aimed to address the question whether aldosterone production is modulated in a zG-depleted *Klotho* mouse model. To date, different *in vivo* studies had shown the interrelation of *Klotho* and CYP11B2 and aldosterone synthesis in different transgenic *Klotho* mouse models (14–16). In the present study, we explored the role of zG-derived *Klotho* on systemic aldosterone production in zG-KI mice and human NCI-H295R cells as an *in vitro* model of hyperaldosteronism (17).

Materials and Methods

Generation of Transgenic Mice

Cyp11b2 (aldosterone synthase)^{+Cre}-*Klotho*^{fl/fl} mice

Cyp11b2^{+Cre-ER} mice (18) is a novel mouse line that allows transgenic modifications specifically in zG cells. It is designed to express the tamoxifen-inducible Cre transgene under the control of the zG specific transcript *Cyp11b2*. Conditional *Klotho* knockout (KO) mice were custom-generated by Ozgene (Bentley DC) by flanking exon 2 with loxP sites (manuscript in preparation). The *Cyp11b2*^{+Cre-ER} mice were cross-bred to *Klotho*^{fl/fl} mice to generate zG-depleted *Klotho* mice (zG-KI-KO) under tamoxifen (TMX)-induced Cre recombination. Heterozygosity at the *Cyp11b2* allele was maintained in all experimental animals including control mice (*Cyp11b2*^{+Cre-ER}-*Klotho*^{+/+}) (zG-Cre).

Cyp11b2^{+Cre-ER}-*Klotho*^{fl/fl}-*mTmG* mice

Cyp11b2^{+Cre-ER}-*Klotho*^{fl/fl} mice were crossed with *Gt(ROSA)26Sor^{tm4}(ACTB-tdTomato-EGFP)^{Luof}/J* reporter line (Jackson: 007676) to generate *Cyp11b2*^{+Cre-ER}-*Klotho*^{fl/fl}-*mTmG*. The mice express membrane-targeted red fluorescence before and membrane-targeted green fluorescence after TMX induced Cre recombination (Fig. 1A).

To induce the Cre activity, all mice received the 2 mg/kg of TMX (Sigma; T5648) dissolved in sunflower seed oil (Sigma; S5007) daily by gavage for 5 consecutive days following 2 weeks of recovery before further study.

Metabolic cage studies

After induction of Cre activity, control (zG-Cre) or (zG-KI-KO) female mice were fed constantly with standard diet (KLIBA NAFAG) and received water ad libitum. Animals were placed individually into metabolic cages (Tecniplast) for 3 days, and water and food intake as well as urine production and body weight were measured. Following 2 days of adaptation, urine was collected under mineral oil and stored at -20 °C for ion measurements. On day 3, the animals were anesthetized with isoflurane and venous blood was taken, centrifuged (8000 rpm, 10 minutes at 4 °C) and the plasma was stored at -80 °C. Then, adrenal and kidneys were collected and stored at -80 °C.

All procedures were carried out according to the Swiss animal welfare laws and guidelines for animal care and were approved by the Veterinary Office of the Canton Zurich (license No. 173/2019).

Adrenocortical cell line and primary culture

Human NCI-H295R cells originally from ATCC were cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 medium (DMEM-F12 and




Figure 1. *Klotho* expression is diminished in the zona glomerulosa (zG) in zG-KI-KO mice. A, Specificity of Cre activity was determined in 8-week-old female inducible *CYP11B2*^{+Cre-ER}-*mTmG* mice that received either vehicle or tamoxifen (TMX) (2 mg/kg/day) for 5 consecutive days. Following 2 weeks of recovery, the *CYP11B2*-*Cre-ER*-expressing cells were labeled with green fluorescence due to TMX-induced Cre activity. B, *Klotho* expression and depletion in the adrenal gland was determined by *in situ* hybridization in both zG-KI-KO and zG-Cre animals, indicating specific expression in the zG. C, Following quantification by fluorescence intensity (FL) measurement, reduction of expression was evident in zG-KI-KO animals. Stars represent significance vs corresponding control; **P* less than or equal to .05.

supplements, Gibco Invitrogen). The medium was supplemented with insulin-transferrin selenium (ITS) solution at a final concentration of insulin 10 mg/L, transferrin 5.5 mg/L, and sodium-selenite 6.7 ng/L (ITS). Additionally, penicillin (100 U/mL), streptomycin (100 µg/mL), and 2% ultrosor G (Cytogen) were added (19).

About 70% to 80% confluent NCI-H295R cells were stably transfected either with scramble *Klotho* guide RNA (gRNA) (CRISPR-Cas9 Negative Control crRNA #1, Integrated DNA Technologies, catalog No. 1072544) or a mixture of 2 *Klotho* gRNAs (protospacer sequence of gRNAs is TCCC GTAGCACCTCACTGT and CCTAATGGAGACATTCA TTT) using the NEON Transfection System following the manufacturing protocol from Integrated DNA Technologies with 2-pulse 20 ms, 1300 V.

Additionally, the confluent NCI-H295R cells were seeded in 24-well plates at a concentration of 1×10^5 cells/mL for 24 hours. Cells were then serum-starved overnight and subsequently incubated with 1 µM recombinant human *Klotho* (Sigma; SRP3102) following 30 minutes or 6 hours with 100 nM Ang II (Sigma; A9525), NaCl (9 mM; 12 mM), and KCl (9 mM; 12 mM) and cells were lysed for RNA and protein extraction.

Eight- to 12-week-old female C57BL/6 wild-type mice were anesthetized with isoflurane and adrenal tissues were removed and dissected under anesthesia. Each adrenal gland was cut

into 4 pieces that were transferred into DMEM-F12 containing 3.6 mg/mL collagenase (Sigma; C6885) and were dissociated by MACS shaker for 40 minutes (program 37C_MALT_A_01). DMEM-F12 containing 10% fetal calf serum was added to stop the collagenase activity and single cells were collected via centrifugation at 500g for 5 minutes. Cells were incubated overnight with and without 1 μ M recombinant human Klotho (Sigma; SRP3102) followed by stimulation of 100 nM Ang II (Sigma; A9525), NaCl (9 mM), and KCL (9 mM) for 6 and 24 hours and cells were lysed for RNA and protein extractions.

Determination of urinary and plasma electrolytes

Urinary and plasma levels of calcium, phosphate, potassium, magnesium, and creatinine were measured with a UniCel Dx C 800 Synchron Clinical System (Beckman Coulter) in the Zurich Integrative Rodent Physiology (ZIRP) facility.

Plasma levels of adrenocorticotropin (ACTH) (MDB; M046006, RRID: AB_2893258) and plasma renin concentration were determined by enzyme-linked immunosorbent assay and radioimmunoassay techniques, respectively, according to the manufacturers' protocols as described previously (20).

Determination of plasma steroids

For functional assessment of mouse steroid hormone levels, liquid chromatography–tandem mass spectrometry was performed as described previously (21).

RNA isolation and semiquantitative real-time polymerase chain reaction

RNA was isolated from mouse adrenal and kidney tissues, human NCI-H295R cells, and mouse primary adrenal cells using the Quick-RNA MiniPrep (ZYMO Research; R1055) according to instructions provided by the manufacturer. Purified RNA was transcribed to complementary DNA (TaqMan Reverse Transcription Kit, Applied Biosystems), which was later used as template for the polymerase chain reaction. The relative expression of the genes of interest was quantified using sequence-specific forward and reverse primers together with sequence-specific probes labeled with reporter (5'-end, FAM) and quencher (3'-end, TAMRA) dyes. Custom-designed primers and probes were synthesized by Microsynth, whereas commercially available primers were purchased from Applied Biosystems (Supplementary Tables 1 and 2 (22)). *Ppib* (peptidylpropyl isomerase B) and *HPRT* (hypoxanthine guanine phosphoribosyltransferase) were used

as housekeeping genes. The relative fold change was calculated according to the formula $2^{(Ct(\text{gene of interest}) - Ct(\text{reference gene}))}$.

RNAscope in situ hybridization

Mouse adrenals were freshly harvested under anesthesia and processed for embedding (O.C.T. embedding matrix; Cell Path). Embedded and frozen adrenals were cut into 12- μ m thick sections, mounted onto Superfrost Plus slides (Thermo Fisher Scientific), and then stored at -80°C until further use. Slides were fixed in 10% neutral-buffered formalin for 15 minutes at 4°C and were dehydrated in gradient ethanol solution. Sections were used for manual RNAscope assay using RNAscope detection kit (Advanced Cell Diagnostics). Probes were ordered from Advanced Cell Diagnostics using the custom probe design service.

Immunofluorescence staining

As described previously (23), adrenal glands were sliced into 6- μ m thick sections using the cryostat microtome (Thermo Scientific) and sections were placed in ice-cold phosphate-buffered saline (PBS). Tissue sections were permeabilized with PBS including 0.1% Tween detergent for 5 minutes. Tissues were blocked with 5% goat serum and then incubated with the 1:100 diluted CYP11B1 (RRID: AB_3076259) and CYP11B2 (RRID: AB_3076258) antibodies (Gomez-Sanchez) in 1% bovine serum albumin (w/v) in PBS-T overnight at 4°C . Sections were washed with PBS 3 times and incubated with 1:500 diluted antimouse (RRID: AB_2338902) and antirabbit (RRID: AB_2338078) Alexa 647 (Jackson), respectively. For nuclear counterstaining, 20 μ M Hoechst 33342 (Invitrogen H3570) was used. After washing 3 times, coverslips were mounted onto the slides with mounting medium FluorSave (Millipore 345 789).

Western blot

Western blots were performed with mouse adrenal and human NCI-H295R cell total protein obtained by homogenization in radioimmunoprecipitation assay buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% deoxycholate acid sodium salt supplemented with phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor cocktail (Roche, 04 693 159 001). Total proteins were separated by electrophoresis in 10% sodium dodecyl sulfate–polyacrylamide gels and transferred to nitrocellulose membranes (Bio-Rad). After blocking with 5% powdered milk in 0.1% TBS-Tween

Table 1. Primary and secondary antibodies used for Western blot

Primary antibody	Species	Dilution	Expected size (kDa)	Company	RRID
pERK1/2	Rabbit	1:2000	42–44	Cell Signaling	AB_331646
Total ERK1/2	Rabbit	1:2000	42–44	Cell Signaling	AB_330744
StAR	Rabbit	1:1000	28	Cell Signaling	AB_10889737
β -Actin	Mouse	1:500	43	Merck Millipore	AB_2571580
β -Tubulin	Rabbit	1:1000	52	Cell Signaling	AB_823664
Secondary antibody		Dilution		Company	RRID
Antimouse (HRP)		1:5000		Cytiva	AB_772210
Antirabbit (HRP conjugated)		1:5000		Cytiva	AB_772191

Abbreviations: ERK, extracellularly regulated kinase; HRP, horseradish peroxidase.

buffer, membranes were incubated overnight at 4 °C with primary antibodies (Table 1). After extensive washing with TBS-Tween buffer, membranes were further incubated with appropriate secondary antibodies (see Table 1) for 1 hour at room temperature and finally were exposed to chemiluminescent substrate. Protein signals were detected on an LAS-4000 Luminescent Image Analyzer and the signals were quantified with Image J. The expression of the proteins of interest was normalized to the abundance of β -actin and β -tubulin.

Statistics

Data are represented as mean \pm SEM. Significance was tested using a one-way analysis of variance with Bonferroni post hoc

correction. *P* values smaller than .05 were considered statistically significant.

Software used for analysis were Fiji/ImageJ and GraphPad Prism 5 (GraphPad Software).

Results

Klotho Modulates *CYP11B2* Expression in Human NCI-H295R Adrenocortical Cells in Response to Angiotensin II

NCI-H295R cells are a suitable model for the study of human adrenal cortex steroidogenesis signaling pathways. To study whether endogenous Klotho depletion affects regulation of adrenal steroidogenesis in response to Ang II, we modulated




Figure 2. *CYP11B1* and *CYP11B2* messenger RNA (mRNA) expression level in Klotho-depleted NCI-H295R cells. A, Endogenous *Klotho* mRNA expression in KI guide RNA (gRNA)-transfected NCI-H295R. B, *CYP11B2* and *CYP11B1* mRNA expression following 6 hours of angiotensin II stimulation in KI gRNA-transfected NCI-H295R. C, *CYP11B2* and *CYP11B1* mRNA expression following 6 hours of 12 mM KCl stimulation in NCI-H295R cells transfected with KI gRNAs leading to Klotho deficiency. mRNA expression levels of genes were normalized to housekeeping gene hypoxanthine guanine phosphoribosyltransferase (*HPRT*). Data are presented as mean \pm SEM (n = 3 per group). Stars represent significance vs corresponding control. NS, not significant; ****P* less than or equal to .001; *****P* less than or equal to .0001.

Klotho gene expression using CRISPR-Cas-9 technology in NCI-H295R cells. Thereby, endogenous *Klotho* gene was diminished up to 70% in KI gRNA-transfected cells as shown in Fig. 2A. *Klotho*-depleted NCI-H295R cells displayed no change of *CYP11B2* gene expression at baseline. However, following both Ang II and high potassium stimulation, *Klotho*-depleted NCI-H295R cells showed significantly higher *CYP11B2* gene expression compared to control cells with no change in *CYP11B1* expression (Fig. 2B and 2C), suggesting a specific role of adrenal-derived *Klotho* on aldosterone synthesis.

NCI-H295R cells have been shown to respond to Ang II, triggering extracellularly regulated kinase (ERK1/2) phosphorylation in a transient fashion (24). In primary cultures of rat adrenal glomerulosa cells, Ang II activates the ERK1/2 signaling pathways and results in an increase in *STAR* expression, steroidogenic enzymes, and steroid synthesis (25, 26). To explore whether recombinant *Klotho* protein might affect the ERK1/2 signaling pathway, NCI-H295R cells were incubated with and without *Klotho* following 30 minutes of either Ang II or potassium stimulation, the main stimulators of aldosterone production (27). As shown in Fig. 3, *Klotho* did not affect the acute response of NCI-H295R cells to Ang II or potassium regarding ERK1/2




Figure 3. Erk1/2 phosphorylation on *Klotho* treatment and potassium or angiotensin II (Ang II) stimulation in NCI-H295R cells. Representative Western blot of ERK1/2 phosphorylation on overnight *Klotho*-treated NCI-H295R cells following 30 minutes of either Ang II or potassium (KCl) stimulation. β -Tubulin has been used as loading control.

phosphorylation, indicating only minor, if any, effects of *Klotho* on ERK1/2 signaling under acute stimulation of Ang II and potassium in NCI-H295R cells.

Recombinant *Klotho* Downregulates *CYP11B2* and Regulatory Transcription Factors Expression in Primary Adrenal Cells

To further investigate *Klotho*'s role in the regulation of aldosterone synthesis, we incubated mouse primary adrenal cells with potassium in the presence and absence of recombinant *Klotho* protein. As expected, potassium induced *CYP11B2* gene expression up to several-fold in comparison to control cells, whereas the recombinant *Klotho* treatment significantly decreased *CYP11B2* expression, suggesting a negative regulatory role of *Klotho* on *CYP11B2* expression (Fig. 4A). The inhibitory role of *Klotho* on *CYP11B2* expression was further confirmed by decreased expression of *Nr4a1* and *Nr4a2* on potassium stimulation (Fig. 4B and 4C).

Zona Glomerulosa-Specific Reduction of *Klotho* Expression In Vivo

The Cre/loxP system has been used extensively for conditional gene manipulation in mice. As a marker of Cre-ER activity, we used a double-fluorescent Cre reporter mouse expressing membrane-targeted tandem dimer Tomato (mT) prior to Cre-mediated excision and membrane-targeted green fluorescent protein (mG) following excision (28). To specifically target *CYP11B2*-positive cells, we used inducible *CYP11B2*^{+Cre}-mTmG mice. Specifically, 8-week-old female mice received either vehicle or tamoxifen (TMX, 2 mg/kg/day) for 5 days. Two weeks following TMX treatment, we observed robust and specific marking of zG cells with green fluorescence due to TMX-induced Cre activity (Fig. 1A). To deplete *Klotho* in *CYP11B2*-expressing cells, *Klotho*^{fl/fl} and *Klotho*^{Wt} were crossed to *Cyp11b2*^{+Cre-ER}-mTmG to produce *Cyp11b2*^{+Cre-ER}-*Klotho*^{fl/fl}-mTmG (zG-KI-KO) and *Cyp11b2*^{+Cre-ER}-*Klotho*^{Wt}-mTmG (zG-Cre) animals, respectively. zG-KI-KO and zG-Cre mice were treated with




Figure 4. Ex vivo mouse adrenal *Cyp11b1*, *Cyp11b2*, *Nr4a1*, and *Nr4a2* expression level on *Klotho* treatment and potassium stimulation. A, Mouse adrenal *Cyp11B2* messenger RNA (mRNA) expression level on overnight recombinant *Klotho* treatment and 6 hours' potassium (KCl) stimulation in female C57BL/6 wild-type mice. NaCl group is considered as control for KCl. B, Mouse adrenal *Nr4a2* and C, *Nr4a1* mRNA expression level on overnight recombinant *Klotho* treatment and 6 hours' KCl stimulation in female C57BL/6 wild-type mice. mRNA expression levels of genes were normalized to housekeeping gene peptidylpropyl isomerase B (*Ppib*). Data are presented as mean \pm SEM (n = 3-4 per group). Stars represent significance vs corresponding control. **P* less than or equal to .05; ***P* less than or equal to .01.

TMX, as discussed earlier, and examined for *Klotho* expression in the adrenal gland by in situ hybridization. *Klotho* was detectable in zG cells of zG-Cre mice (Fig. 1B) and was diminished by about 65% in zG-KI-KO mice compared to zG-Cre animals as evidenced by fluorescence intensity measurement (Fig. 1C). We further confirmed that the expression of *Klotho* remained unchanged in the kidney of zG-KI-KO mice compared to zG-Cre (data not shown), suggesting tissue-specific *Klotho* depletion in our inducible mouse model.

Zona Glomerulosa-Depleted *Klotho* in Female Mice Increased *CYP11B2* and Regulatory Transcription Factors Expression Without Effects on Systemic Aldosterone Levels

To explore the effect of zG-specific *Klotho* depletion on aldosterone production, we assessed the expression of

11 β -hydroxylase (*CYP11B1* gene), aldosterone synthase (*CYP11B2* gene), and 2 transcription factors, nerve growth factor-induced clone B NGFIB (*Nr4a1*) and Nur-related factor 1 Nurr1 (*Nr4a2*) that affect *CYP11B2* expression. *Nr4a2* has been reported to upregulate aldosterone synthase expression in NCI-H295R cells and proposed to have clinical importance, since its expression levels are upregulated in aldosterone-producing adenomas and correlate with aldosterone synthase expression levels (29, 30). Notably, expression of *CYP11B2*, *Nr4a1*, and *Nr4a2* were each increased in zG-KI-KO female mice, but not in males, comparing to the age-matched zG-Cre group (Fig. 5A and 5B; male data not shown), suggesting activation of the mineralocorticoid gene pathway activation, whereas *CYP11B1* and *StAR* expressions were not affected.

Next, we assessed the response of steroids in the mineralocorticoid pathway to zG-specific *Klotho* ablation. While hyperaldosteronism has been described in various *Klotho*-deficient




Figure 5. Adrenal *Cyp11b1*, *Cyp11b2*, *Nr4a1*, and *Nr4a2* and *StAR* expression level in zG-KI-KO mice. A, Adrenal messenger RNA (mRNA) expression of *Cyp11b2* and *Cyp11b1*; B, *Nr4a1* and *Nr4a2*; and C, *StAR* mRNA and protein levels in 12-week-old zG-Cre and zG-KI-KO female mice after induction of Cre activity. mRNA expression levels of genes were normalized to housekeeping gene peptidylpropyl isomerase B (*Ppib*). Data are presented as mean \pm SEM (n = 8 per group). Stars represent significance vs corresponding control; *P less than or equal to .05.

mouse models in the literature (14-16), we observed no change in plasma aldosterone levels (or its precursors) in zG-KI-KO mice compared to controls, suggesting a minor effect of zG-specific Klotho on aldosterone production (Fig. 6A). In line with unchanged aldosterone levels, we detected no significant change in either plasma renin concentration (Fig. 6B) or renal renin expression (data not shown) in the zG-KI-KO group compared to control mice. As a potential indicator of stress, a significant increase in plasma corticosterone levels was noted in zG-KI-KO mice (see Fig. 6A). Since relative change of plasma corticosterone concentration is regulated by the hypothalamic-pituitary-adrenal axis in response to stress (31, 32), we checked the plasma ACTH level in zG-KI-KO mice. Despite increased plasma ACTH levels observed in KI-deficient mice (15), plasma ACTH levels were comparable between zG-KI-KO and control mice (Fig. 6C). Moreover, no differences in plasma potassium levels were evident between the genotypes as well as other measured electrolytes (Ca^{++} , Pi, Mg^{++} ; Fig. 6D).

Discussion

In the present study, we examined the influence of Klotho, a protein implicated in a variety of conditions including electrolyte balance, on aldosterone synthase expression within the context of adrenal physiology. Using different experimental approaches, we have delineated a novel role for zG-derived Klotho in modulating aldosterone synthase (*CYP11B2*) expression in young female mice. Our findings suggest that Klotho directly downregulates *CYP11B2* and its regulatory transcription factors, specifically Nr4a1 and Nr4a2, without overtly affecting plasma aldosterone levels.

Klotho is a gene that was initially described in the context of aging (1-4). It is primarily expressed in the kidney, where it regulates fluid and electrolyte homeostasis. The interplay between Klotho and adrenal steroidogenesis has been under investigation, given its potential implications for pathophysiological states such as primary aldosteronism (14-16). Our data provide evidence supporting the hypothesis that Klotho acts as a negative regulator of *CYP11B2* gene expression. This




Figure 6. Hormonal workup and serum electrolytes in zG-KI-KO mice. A, Plasma levels of steroid hormones including aldosterone, 11-deoxycorticosterone (11-DOC), corticosterone, 18 hydroxy-corticosterone (18OH), 11-dehydro-corticosterone (11-DH); B, plasma renin; and C, adrenocorticotropin (ACTH) concentration in 12-week-old zG-Cre and zG-KI-KO female mice after Cre activation. D, Plasma values of potassium (K^+), calcium (Ca^{2+}), phosphate (Pi), and magnesium (Mg^{2+}) of female zG-KI-KO mice after Cre activity induction. Stars represent significance versus corresponding control; **P* less than or equal to .05.

regulatory role is substantiated by our *in vitro* experiments, where *Klotho* depletion using CRISPR-Cas-9 technology resulted in elevated *CYP11B2* expression following Ang II stimulation in adrenocortical NCI-H295R cells. The specificity of this regulation was further emphasized by the lack of change in *CYP11B1* expression.

Notably, the ERK1/2 signaling pathway, a well-established mediator of Ang II-induced aldosterone synthesis, did not appear to be influenced by *Klotho* under acute stimulation conditions. This finding contrasts with the existing literature that links *Klotho* with various signaling pathways, suggesting that *Klotho*'s regulatory mechanisms may be pathway-selective or context-dependent.

Our *ex vivo* and *in vivo* experiments further substantiated these *in vitro* data. We made use of a novel mouse model for zG-specific reduction of *Klotho*, achieved via a Cre/loxP approach, which led to an upregulation of *CYP11B2* and transcription factors *Nr4a1* and *Nr4a2*, key players in mineralocorticoid synthesis (33). This upregulation was evident in female but not in male mice. Intriguingly, despite the molecular evidence of enhanced aldosterone synthesis pathway activity, plasma aldosterone levels remained unchanged in zG-specific *Klotho*-depleted mice. Thereby, our results suggest that while zG-specific *Klotho* depletion leads to molecular changes indicative of stimulated aldosterone synthesis pathways, these alterations are not sufficient to induce a state of hyperaldosteronism. There are a number of potential reasons to explain this inconsistency: First, it may be attributed to the subtlety of *in vivo* changes, which, although sufficient to drive gene expression, do not affect systemic hormone profiles. Second, *in vivo* compensatory mechanisms may be in place, which could include hormonal feedback loops and intraglandular homeostasis that effectively dampen the increase in local gene expression, thus maintaining systemic hormonal balance. Third, the utilization of young mice in a physiological state of equilibrium—absent any external stressors such as a low-sodium diet or pharmacological provocations—raises the possibility of a homeostatic capacity to buffer genetic perturbations. Fourth, the developmental stage of the animals may reflect a window of heightened compensatory efficiency, preventing the full phenotypic expression of *Klotho*'s influence on aldosterone levels. Finally, sex-dependent differences might have played a role that can readily affect an adrenal phenotype.

The degree of *in vivo* *Klotho* modulation might be a crucial determinant of the phenotypic outcome. In our study, a reduction in *Klotho* expression did not reach that of a complete KO, which could be a critical threshold for the manifestation of a systemic phenotype. Indeed, the requirement for a more substantial or complete depletion of *Klotho* to elicit pronounced changes highlights the possibility that adrenal *Klotho* may exert its effects in a dose-dependent manner, where only severe reductions result in noticeable systemic alterations. Furthermore, the specificity of *Klotho*'s actions within the adrenal context may delineate a model where its role is confined to fine-tuned local regulation rather than influencing systemic hormonal levels. The sensitivity and timing of systemic aldosterone measurements may also account for the absence of detectable differences. Subtle changes or transient elevations in hormone levels could have eluded our detection methods, emphasizing the need for assays with higher sensitivity or longitudinal monitoring to capture peak hormonal fluctuations. No effect on electrolyte

homeostasis, however, was further evidence of a lack of hyperaldosteronism in this model.

This study also underscores the discrepancy that can arise between *in vitro* findings and *in vivo* phenotyping. While *Klotho* depletion in NCI-H295R cells resulted in a marked upregulation of *CYP11B2* post Ang II stimulation, the *in vivo* context presented a more complex scenario, possibly reflecting the influence of systemic factors and intercellular communications not present in cell cultures.

In conclusion, our data highlight the nuanced role of *Klotho* in adrenal physiology, arguing for a threshold-dependent, homeostatically balanced, and potentially localized regulatory mechanism. This work reinforces the notion that adrenal steroidogenesis is part of a tightly regulated network, with some resistance to singular genetic manipulations. The findings herein provide a foundation for future studies, which should include older animals, male mice, varied physiological stressors, and a broader scope of genetic modifications to fully elucidate *Klotho*'s place within zG physiology.

Acknowledgments

We thank the Zürich Integrative Rodent Physiology (ZIRP) Core facility for biochemical analysis and free access to surgery rooms and metabolic cages. We acknowledge Dr Richard Züllig for his support regarding the animal experiments. The authors would also like to thank Dr Celso Gomez Sanchez for kindly providing the antibody against CYP11B1 and CYP11B2.

Funding

This work was supported by the Swiss National Centre for Competence in Research “Kidney.CH” (to F.B. and J.L.) and Swiss National Science Foundation (project grant No. 310030L_182700/1 to F.B.). The work was further supported by the Promedica Stiftung (to F.B.) and the Clinical Research Priority Program of the University of Zurich for the CRPP HYRENE (to F.B. and J.L.) and by the University Research Priority Program of the University of Zurich (URPP) ITINERARE—Innovative Therapies in Rare Diseases.”

Author Contributions

C.T., A.D., Y.X., and M.P. conducted the experiments. C.T., A.D., V.F., and Y.X. analyzed the data and interpreted the results. C.T., A.D., and V.F. designed the experiments and interpreted the results. D.T.B., D.L., J.L., V.F., C.H., D.P.R., and F.B. contributed experimental tools. A.D. and F.B. wrote the manuscript. All authors read the manuscript, contributed to editing, and approved the final version.

Disclosures

The authors declare no financial competing interests.

Data Availability

Original data generated and analyzed during this study are included in this published article or in the data repositories listed in “References.”

References

1. Kuro-o M, Matsumura Y, Aizawa H, *et al.* Mutation of the mouse *klotho* gene leads to a syndrome resembling ageing. *Nature*. 1997;390(6655):45-51.
2. Kuro-o M. *Klotho*. *Pflugers Arch*. 2010;459(2):333-343.
3. Kurosu H, Yamamoto M, Clark JD, *et al.* Suppression of aging in mice by the hormone *klotho*. *Science*. 2005;309(5742):1829-1833.
4. Kuro OM. The *klotho* proteins in health and disease. *Nat Rev Nephrol*. 2019;15(1):27-44.
5. Epstein M, Freundlich M. The intersection of mineralocorticoid receptor activation and the FGF23-Klotho cascade: a duopoly that promotes renal and cardiovascular injury. *Nephrol Dial Transplant*. 2022;37(2):211-221.
6. Freundlich M, Gamba G, Rodriguez-Iturbe B. Fibroblast growth factor 23-Klotho and hypertension: experimental and clinical mechanisms. *Pediatr Nephrol*. 2021;36(10):3007-3022.
7. Leifheit-Nestler M, Kirchhoff F, Nespor J, *et al.* Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts. *Nephrol Dial Transplant*. 2018;33(10):1722-1734.
8. Faul C, Amaral AP, Oskouei B, *et al.* FGF23 induces left ventricular hypertrophy. *J Clin Invest*. 2011;121(11):4393-4408.
9. Imazu M, Takahama H, Asanuma H, *et al.* Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. *Am J Physiol Heart Circ Physiol*. 2014;307(10):H1504-H1511.
10. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and *Klotho*: physiology and pathophysiology of an endocrine network of mineral metabolism. *Annu Rev Physiol*. 2013;75:503-533.
11. Zanchi C, Locatelli M, Benigni A, *et al.* Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. *PLoS One*. 2013;8(8):e70775.
12. Prie D, Forand A, Francoz C, *et al.* Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list. *PLoS One*. 2013;8(6):e66182.
13. Zhang B, Umbach AT, Chen H, *et al.* Up-regulation of FGF23 release by aldosterone. *Biochem Biophys Res Commun*. 2016;470(2):384-390.
14. Zhou X, Chen K, Wang Y, Schuman M, Lei H, Sun Z. Antiaging gene *Klotho* regulates adrenal CYP11B2 expression and aldosterone synthesis. *J Am Soc Nephrol*. 2016;27(6):1765-1776.
15. Fischer SS, Kempe DS, Leibrock CB, *et al.* Hyperaldosteronism in *Klotho*-deficient mice. *Am J Physiol Renal Physiol*. 2010;299(5):F1171-F1177.
16. Voelkl J, Alesutan I, Leibrock CB, *et al.* Spironolactone ameliorates PIT1-dependent vascular osteoinduction in *klotho*-hypomorphic mice. *J Clin Invest*. 2013;123(2):812-822.
17. Lichtenauer UD, Shapiro I, Osswald A, *et al.* Characterization of NCI-H295R cells as an in vitro model of hyperaldosteronism. *Horm Metab Res*. 2013;45(2):124-129.
18. Berber M, Leng S, Wengi A, *et al.* Calcineurin regulates aldosterone production via dephosphorylation of NFATC4. *JCI Insight*. 2023;8(14):e157027.
19. Sigala S, Bothou C, Penton D, *et al.* A comprehensive investigation of steroidogenic signaling in classical and new experimental cell models of adrenocortical carcinoma. *Cells*. 2022;11(9):1439.
20. Perez-Rivas LG, Rhayem Y, Sabrautski S, *et al.* Genetic characterization of a mouse line with primary aldosteronism. *J Mol Endocrinol*. 2017;58(2):67-78.
21. Peitzsch M, Dekkers T, Haase M, *et al.* An LC-MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism. *J Steroid Biochem Mol Biol*. 2015;145:75-84.
22. Daryadel AT, Xie C, Peitzsch Y, *et al.* Data from: Supplementary Information to: Zona glomerulosa derived *Klotho* modulates aldosterone synthase expression in young female mice. 2024. <https://doi.org/10.5281/zenodo.10807770>.
23. Leng S, Pignatti E, Khetani RS, *et al.* beta-Catenin and FGFR2 regulate postnatal rosette-based adrenocortical morphogenesis. *Nat Commun*. 2020;11(1):1680.
24. Mori Sequeiros Garcia MM, Cohen Sabban JM, Dattilo MA, *et al.* Angiotensin II-upregulated MAP kinase phosphatase-3 modulates FOXO1 and p21 in adrenocortical H295R cells. *Heliyon*. 2020;6(3):e03519.
25. Otis M, Gallo-Payet N. Role of MAPKs in angiotensin II-induced steroidogenesis in rat glomerulosa cells. *Mol Cell Endocrinol*. 2007;265-266:126-130.
26. Otis M, Campbell S, Payet MD, Gallo-Payet N. Angiotensin II stimulates protein synthesis and inhibits proliferation in primary cultures of rat adrenal glomerulosa cells. *Endocrinology*. 2005;146(2):633-642.
27. Romero DG, Plonczynski M, Vergara GR, Gomez-Sanchez EP, Gomez-Sanchez CE. Angiotensin II early regulated genes in H295R human adrenocortical cells. *Physiol Genomics*. 2004;19(1):106-116.
28. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent cre reporter mouse. *Genesis*. 2007;45(9):593-605.
29. Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE. The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. *Mol Endocrinol*. 2004;18(2):279-290.
30. Lu L, Suzuki T, Yoshikawa Y, *et al.* Nur-related factor 1 and nerve growth factor-induced clone B in human adrenal cortex and its disorders. *J Clin Endocrinol Metab*. 2004;89(8):4113-4118.
31. Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. *Dialogues Clin Neurosci*. 2006;8(4):383-395.
32. Stephens MA, Wand G. Stress and the HPA axis: role of glucocorticoids in alcohol dependence. *Alcohol Res*. 2012;34(4):468-483.
33. Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE. The NGFIB family of nuclear receptors regulates adrenal aldosterone production. *Mol Endocrinol*. 2003;26:26.